Navigation Links
Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Date:5/1/2008

-- Presentations highlight Palomid 529 as an inhibitor of macular

degeneration, diabetic retinopathy and retinal scaring from retinal

detachment in animal disease models ---

JAMAICA PLAIN, Mass., May 1 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. today announced it has presented two presentations at the 2008 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) describing the activity of Palomid 529 in a series of models of retinal disease notably macular degeneration, diabetic retinopathy and retinal fibrosis.

P529 is a non-steroidal, synthetic, small molecule drug created through computational design, synthetic and medicinal chemistry, the result of three generations of Palomid design work. Palomid's broad activity as an anti-angiogenic and anti-proliferative agent is shown to reside in its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway as a TORC1/TORC2 inhibitor.

The first of the two presentations, "Palomid 529, a Non-Steroidal Small Molecule Anti-Angiogenic Agent Inhibits Retinal and Subretinal Neovascularization by Inhibiting the PI3K/Akt/mTOR Pathway", was given as an oral presentation by Dr. David Sherris, President and CEO of Paloma Pharmaceuticals. The second presentation, "Muller Cell Proliferation and Glial Scar Formation Is Reduced Following Experimental Retinal Detachment Using Palomid 529, an Inhibitor of the Akt/mTOR Pathway", was given by the Drs. Geoffrey P. Lewis and Steven. K. Fisher, presented by Dr. Ethan A. Chapin, of the Neuroscience Research Institute, Neuroscience Research Institute, MCD Biology, University of California-Santa Barbara, Santa Barbara, CA.

"Ocular diseases of both retinal and sub-retinal origin, namely diabetic retinopathy and age-related macular degeneration, are a significant problem in our aging population. In order to create a drug to optimally treat such diseases one needs to prevent or inhibit disease pr
'/>"/>

SOURCE Paloma Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
2. Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology
3. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
4. Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms
5. Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
7. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
8. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
9. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
10. Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings
11. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...ence Call Scheduled Tuesday, August 5, 2008 at 11:...e-FirstCall/ -- Almost Family, Inc.,(Nasdaq: AFAM...sing,services, announced today that it will report..., 2008 on Tuesday, August 5, 2008, before the,mark... will begin at 11:00 a.m. ET on,August 5, 2008 and...
(Date:7/23/2008)...ON, N.J., July 23 /PRNewswire-USNewswire/ -- The N...lity and Patient Safety has,received a planning gr...dation (RWJF) to develop a proposal for improving ...nt will help determine over the next six months wh...ning Forces for Quality initiative,which is focus...
(Date:7/23/2008)..., China, July 23 /Xinhua-PRNewswire-FirstCall/ -- ...letin Board: GTEC) ("Genesis" or,the "Company"), a...public,of China, held a Board of Directors meeting...appointed to serve on the Board of Directors of th...on Committee were formed., Mr. Michael Marks was ...
(Date:7/23/2008)...ERSBURG, Fla., July 23 /PRNewswire/ -- Laura Kolkm...gnized health information exchange,consulting firm...hcare,Information and Management Systems Society (...ing Committee., The HIE Steering Committee, which...ng providers, payers, vendors, consultants and lif...
Breaking Medicine News(10 mins):Health News:Almost Family, Inc. to Report Second Quarter 2008 Financial Results 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2
...Texas observed that Viagra could be used to treat ...but based on a small experiment in healthy young m...ly to people with chronic heart and lung disease. ...ul in treating people with pulmonary hypertension ...
... soon be available for patients needing root canal...end to the dreaded drill. Scientists say laser tre...thout damaging the healthy nerve. They added that...damage to the rest of the teeth. Researchers said ...
...sible connection to autism. A study in this week's...ith autism are no more likely than those without i.... // Study investigators from Boston University id...ompared them to children without autism. They revi...
...s that pre and post exercise stretching does littl...gym routines or exercise classes// you'll be well ...he session to prepare your muscles. It's always as...the following day and reduce the risk of injury li...
Other Medicine News:
(Date:7/23/2008)...- Sound Pharmaceuticals (SPI) has filed,an Investi... clinical,testing of a proprietary formulation of ... hearing loss or ototoxicity. The oral capsule,con...ced stage lung cancer,and head and neck cancer pat...marks the second development program for SPI to en...
(Date:7/23/2008)... FluoroPharma Inc., a company developing,breakthro...sion Tomography,(PET) market, announced positive P...beled tracer for myocardial perfusion imaging. BFP... to complete Phase I clinical,development., BFPET...ood flow in the,heart (myocardial perfusion). Myoc...
(Date:7/23/2008)...ire/ -- InCode BioPharmaceutics, Inc.,an emerging...nical test,results demonstrating the utility of th... the rare chronic blood disorder paroxysmal noctur...l be presented at the XXII,International Complemen...08., The only treatment currently available for P...
(Date:7/23/2008)... Work with Protein Therapeutics that Mod...AMBRIDGE, Mass., July 23 /- Taligen T...a corporate growth plan with the,appointment of Ab...d the,establishment of its headquarters in Cambrid...D., a co-founder of the company who remains presid...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 1Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 2Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 3Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 4AAHC Examines Nations Clinical Trials Infrastructure 620 1AAHC Examines Nations Clinical Trials Infrastructure 620 2Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 1Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 2Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 3Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 4Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 1Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 2Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 3Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 4Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 5Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 6Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 7Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 8Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 9Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 10Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 11Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 12
...THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007...ced final results of a U.S.,Phase 2 study of Proel...ymptoms of uterine fibroids. This study suggests t...ally highly,significant improvement in symptoms as...ll tolerated., Study Details and Results , This 12...
...PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - A...nced the publication by its,majority-owned subsidi...strating the anti-proliferative effect of the siRN...f its lead anti-cancer,compound, CALAA-01., The pa...eotide,Reductase Subunit RRM2 Reduce Cell Prolifer...
Other Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 2Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 3